Next Article in Journal
The Predictive Value of Plasma Brain Natriuretic Peptide and Galectin-3 in Elderly Patients Admitted for Heart Failure
Next Article in Special Issue
The Role of Statins in the Management of Patients Undergoing Coronary Artery Bypass Grafting
Previous Article in Journal
The Role of Vitamin E in the Treatment of NAFLD
Previous Article in Special Issue
Regulation of Sphingolipid Metabolism by MicroRNAs: A Potential Approach to Alleviate Atherosclerosis
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessReview

Judicious Use of Lipid Lowering Agents in the Management of NAFLD

Department of Medicine, Geisinger Medical Center, Danville, PA 17821, USA
Drexel University College of Medicine, Philadelphia, PA 19104, USA
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94304, USA
Author to whom correspondence should be addressed.
Diseases 2018, 6(4), 87;
Received: 9 August 2018 / Revised: 15 September 2018 / Accepted: 16 September 2018 / Published: 24 September 2018
PDF [736 KB, uploaded 24 September 2018]


Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world. NAFLD encompasses a spectrum of histological features, including steatosis, steatohepatitis with balloon degeneration, and hepatic fibrosis leading to cirrhosis. In patients with advanced liver damage, NAFLD is associated with an increased risk of hepatocellular carcinoma. Diabetes mellitus, hypertension, and dyslipidemia are components of metabolic syndrome and are commonly associated with NAFLD. Cardiovascular disease is the leading cause of mortality in patients with NAFLD. Therefore, it is important to pre-emptively identify and proactively treat conditions like hyperlipidemia in an effort to favorably modify the risk factors associated with cardiovascular events in patients with NAFLD. The management of hyperlipidemia has been shown to reduce cardiovascular mortality and improve histological damage/biochemical abnormalities associated with non-alcoholic steatohepatitis (NASH), a subset of NAFLD with advance liver damage. There are no formal guidelines available regarding the use of anti-hyperlipidemic drugs, as prospective data are lacking. The focus of this article is to discuss the utility of lipid-lowering drugs in patients with NAFLD. View Full-Text
Keywords: NAFLD; NASH; hepatic fibrosis; hyperlipidemia; statins NAFLD; NASH; hepatic fibrosis; hyperlipidemia; statins

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Iqbal, U.; Perumpail, B.J.; John, N.; Sallam, S.; Shah, N.D.; Kwong, W.; Cholankeril, G.; Kim, D.; Ahmed, A. Judicious Use of Lipid Lowering Agents in the Management of NAFLD. Diseases 2018, 6, 87.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top